Background Myeloma causes profound immunodeficiency and recurrent, serious infections.
Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of …

Multiple myeloma (MM) is a malignancy of clonal plasma cells, resulting in an increased
production of ineffective immunoglobulins with suppression of non-involved …

Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To
estimate the risk of bacterial and viral infections in multiple myeloma patients, we used …

The introduction of stem cell transplantation and the novel anti-myeloma agents, bortezomib,
thalidomide, and lenalidomide, have improved the outcome of patients with multiple …

Few studies have evaluated the role of antibacterial prophylaxis during neutropenia in
patients with multiple myeloma undergoing autologous hematopoietic stem cell …

Infections represent a major cause of morbidity and mortality in multiple myeloma and are
linked to both therapy-and disease-related factors. Although it has been suggested that the …

Infections are a major cause of morbidity and mortality in multiple myeloma. The increased
risk for bacterial and viral infections results mainly from the disease‐inherent and treatment …

The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome
inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes …

We defined the epidemiology and clinical predictors of infection in patients with multiple
myeloma (MM) receiving immunomodulatory drugs (IM iDs), proteasome inhibitors (PI) and …